RIC8A and cancer: Based on the lack of mutations identified in clinical breast cancer samples as well as the lack of evidence from cancer genome sequencing studies indicating involvement of RIC8A [22,23], we postulated that RIC8A inactivation could either be a rare genetic event in breast cancer, or possibly, its inactivation in clinical samples could take place more often through other mechanisms, not involving direct truncating mutations or methylation.